Stockreport

Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet's Fixed Dose Combination Program [Yahoo! Finance]

Sagimet Biosciences Inc. - Series A  (SGMT) 
PDF Collaboration supports Sagimet's fixed-dose combination (FDC) program currently in clinical development Sagimet's Phase 1 pharmacokinetic (PK) trial of combination of [Read more]